



URGENT: IMMEDIATE ACTION REQUIRED

To: ALL HOSPITAL SITES
From: National Emergency Blood Management Committee (NEBMC)*
Subject: RECOVERY PHASE ADVISORY

National Inventory SHORTAGE Advisory – Recovery

Date and time of issue	2019-07-26 09:00 (EDT)
Inventory Availability Phase	RECOVERY PHASE (Transition from Amber towards Green Phase)
Product(s)	Subcutaneous Immunoglobulin (SCIg)
Description	<p>The supply of Cuvitru® is recovering and current Canadian Blood Services inventories can allow clinics to start urgent patients on SCIg therapy in a controlled manner. We anticipate being through Recovery to Green Phase by September 2019, though this will be re-evaluated weekly.</p> <p>A graded approach to new patient starts on SCIg is essential to ensure product inventory does not become too depleted during the recovery phase. A national group of clinical specialists in neurology and immunology have developed recommendations to guide the decision of patient urgency for new SCIg starts. The original communication will be posted on the Canadian Immunodeficiencies Patient Organization website next week: http://www.cipo.ca/. The NEBMC has reviewed and supports the recommendations, which are listed below.</p>
Impact on hospitals	<p>Hospitals/clinics can notify treaters that they can initiate SCIg therapy for new patients who urgently require treatment. Priority should be given to those patients who cannot receive IVIg. Reasons that patients may be unable to receive IVIg include:</p> <ol style="list-style-type: none"> 1. Intravenous access is not possible or would require unnecessarily invasive means to achieve IV access. 2. The patient has had significant adverse reactions with IVIg products despite premedication. 3. Administration of IVIg is not feasible for a given site due to significant lack of resources such as nursing or clinic capacity. (clinical need should take priority) <p>These recommendations are not intended to replace clinical judgement and may not apply to all clinical situations.</p> <p>When initiating any new urgent patients on SCIg therapy:</p> <ul style="list-style-type: none"> • prescribers should consult with their appropriate provincial group (e.g. blood coordinating office, centralized blood bank or infusion clinic) for identification and prioritization as needed. • hospitals/clinics should provide anonymized patient information to their appropriate provincial group and Canadian Blood Services. This information is for monitoring purposes only and a template of required information will be posted on Canadian Blood Service's website next week: https://blood.ca/en/hospital-services/customer-service/communications/inventory-advisories. The NEBMC strongly recommends use of this template, which will help to monitor new patient starts and assist with national SCIg demand forecasting. <p><i>If you are unsure how consultation and data submission should occur, contact your provincial or territorial NEBMC representative(s), (contact information included in template).</i></p>

	<p>Note:</p> <ul style="list-style-type: none"> • All new urgent patients that meet the above criteria are to receive Cuvitru®. The products Cutaquig® and Hizentra® are to be used for <u>current</u> SCIg patients (for medical reasons or within certain Alberta and Ontario clinics to help reduce demand for Cuvitru®). • SCIg patients may now resume receiving regular supply amounts for home infusion (e.g. 3 months supply as required). • Non-urgent new patients <u>should not</u> yet be started on any SCIg brand without further direction from the NEBMC based on adequacy of inventory levels.
For more information	<p>For additional info, contact:</p> <ol style="list-style-type: none"> 1. Your Hospital Liaison Specialist, Canadian Blood Services 2. Your representative to the Provincial Emergency Blood Management Committee 3. Your representative to your Hospital Emergency Blood Management Committee

**The National Emergency Blood Management Committee is comprised of the National Advisory Committee on Blood and Blood Products, Provincial Territorial Blood Liaison representatives and key Canadian Blood Services personnel. This group will develop recommendations and provide advice to the P/T Ministries of Health, hospitals and regional health authorities, and Canadian Blood Services to support a consistent and coordinated response to critical blood shortages in Canada. For information about the National Blood Shortages Plan, please see: <https://www.nacblood.ca/resources/shortages-plan/index.html>*

A copy of this advisory will be posted on Canadian Blood Services' website: <https://blood.ca/en/hospital-services/customer-service/communications/inventory-advisories>

If you require this advisory in an accessible format, please contact your local Canadian Blood Services Hospital Liaison Specialist.